Decisions

Mike Tremblay September 12, 2019

Market access is wrapped in the politics of health The attention politicians and stakeholders pay to healthcare and its challenges is a keen driver of the ease or difficulty companies experience with drug regulation and market access and has implications through the development process to discovery. How this manifests itself, in part depends on a […]

Mike Tremblay July 4, 2019

It is not unreasonable to have concerns about the cost of medicines. Drug costs are usually influenced by government policies on pricing and reimbursement of medicines themselves. These range from simple discount seeking to more complex approaches such as conditional approvals, and value-based pricing (perhaps a subject for another posting). These can achieve a measure […]

Mike Tremblay July 3, 2019

Discussions on health literacy are increasing as healthcare providers, clinicians, payers and patients consider what this means for healthcare. Having been involved in launching the world’s first digital interactive health channel in the UK in 2000, one thing I learned is not to assume that everyone is alike or has common interests. Healthcare systems are […]

Mike Tremblay March 6, 2019

The relevance of value in establishing the positioning of medicines is the new normal for pharmaceutical marketing. Pharmaceutical companies have customers who are highly constrained by whether healthcare system funding is sustainable long term. Remember, payers think epidemiologically and in multiple years of costed care so industry needs to assess how that can be understood […]

Mike Tremblay March 1, 2015

Good decision-making depend on understanding what goals the decisions serve, and what information and processes we will use to make that decision. It is not unknown for decisions to be made in haste, or with poor understanding of the context, or miscontrue external influences. An example is mismatching the evidence generation process, used to provide […]